Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7528.074 | 0.6238 | 0.2560 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7528.074 | 0.4440 | -0.1018 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7528.074 | 0.4440 | -0.1018 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7528.074 | 0.0384 | -0.9197 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7528.074 | 0.0384 | -0.9197 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7528.074 | 0.0167 | -0.9646 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7528.074 | 0.0167 | -0.9646 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7528.074 | 0.0134 | -0.9716 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7528.074 | 0.0134 | -0.9716 | 1.0143 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 9044.074 | 1.0162 | 1.0494 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 9044.074 | 1.0162 | 1.0494 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 9044.074 | 1.0352 | 1.1075 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 9044.074 | 1.0352 | 1.1075 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 9044.074 | 1.0291 | 1.0887 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 9044.074 | 1.0291 | 1.0887 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 9044.074 | 0.7112 | 0.1940 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 9044.074 | 0.7112 | 0.1940 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 9044.074 | 0.2157 | -0.8038 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 9044.074 | 0.2157 | -0.8038 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 9044.074 | 0.1043 | -0.9347 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 9044.074 | 0.1043 | -0.9347 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 9044.074 | 0.0239 | -0.9930 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 9044.074 | 0.0239 | -0.9930 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 9044.074 | 0.0105 | -0.9980 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 9044.074 | 0.0105 | -0.9980 | 0.6607 |